Annual Total Liabilities
$1.24 B
+$25.56 M+2.10%
December 1, 2024
Summary
- As of March 12, 2025, RARE annual total liabilities is $1.24 billion, with the most recent change of +$25.56 million (+2.10%) on December 1, 2024.
- During the last 3 years, RARE annual total liabilities has risen by +$641.32 million (+106.92%).
- RARE annual total liabilities is now at all-time high.
Performance
RARE Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$1.24 B
+$56.62 M+4.78%
December 1, 2024
Summary
- As of March 12, 2025, RARE quarterly total liabilities is $1.24 billion, with the most recent change of +$56.62 million (+4.78%) on December 1, 2024.
- Over the past year, RARE quarterly total liabilities has increased by +$25.56 million (+2.10%).
- RARE quarterly total liabilities is now at all-time high.
Performance
RARE Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
RARE Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +2.1% | +2.1% |
| 3 y3 years | +106.9% | +106.9% |
| 5 y5 years | +157.7% | +157.7% |
RARE Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +106.9% | at high | +111.2% |
| 5 y | 5-year | at high | +157.7% | at high | +157.7% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Ultragenyx Pharmaceutical Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $1.24 B(+2.1%) | $1.24 B(+4.8%) |
| Sep 2024 | - | $1.18 B(-0.1%) |
| Jun 2024 | - | $1.19 B(+1.6%) |
| Mar 2024 | - | $1.17 B(-4.0%) |
| Dec 2023 | $1.22 B(+1.9%) | $1.22 B(+0.8%) |
| Sep 2023 | - | $1.21 B(+2.0%) |
| Jun 2023 | - | $1.18 B(+1.7%) |
| Mar 2023 | - | $1.16 B(-2.5%) |
| Dec 2022 | $1.19 B(+98.9%) | $1.19 B(+3.8%) |
| Sep 2022 | - | $1.15 B(+78.9%) |
| Jun 2022 | - | $642.55 M(+9.4%) |
| Mar 2022 | - | $587.61 M(-2.0%) |
| Dec 2021 | $599.84 M(-0.9%) | $599.84 M(+8.8%) |
| Sep 2021 | - | $551.13 M(+2.0%) |
| Jun 2021 | - | $540.27 M(-0.5%) |
| Mar 2021 | - | $543.18 M(-10.2%) |
| Dec 2020 | $605.18 M(+25.6%) | $605.18 M(+0.5%) |
| Sep 2020 | - | $602.19 M(-2.6%) |
| Jun 2020 | - | $618.45 M(-0.9%) |
| Mar 2020 | - | $623.99 M(+29.5%) |
| Dec 2019 | $481.73 M(+335.4%) | $481.73 M(+215.5%) |
| Sep 2019 | - | $152.68 M(+9.7%) |
| Jun 2019 | - | $139.14 M(+15.0%) |
| Mar 2019 | - | $121.03 M(+9.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2018 | $110.65 M(+3.1%) | $110.65 M(+7.9%) |
| Sep 2018 | - | $102.55 M(+0.5%) |
| Jun 2018 | - | $102.05 M(+8.9%) |
| Mar 2018 | - | $93.69 M(-12.7%) |
| Dec 2017 | $107.30 M(+61.0%) | $107.30 M(+54.4%) |
| Sep 2017 | - | $69.49 M(+2.1%) |
| Jun 2017 | - | $68.09 M(+18.7%) |
| Mar 2017 | - | $57.34 M(-14.0%) |
| Dec 2016 | $66.65 M(+134.0%) | $66.65 M(+12.4%) |
| Sep 2016 | - | $59.28 M(+55.8%) |
| Jun 2016 | - | $38.06 M(+10.8%) |
| Mar 2016 | - | $34.36 M(+20.7%) |
| Dec 2015 | $28.48 M(+118.7%) | $28.48 M(+12.3%) |
| Sep 2015 | - | $25.37 M(+6.9%) |
| Jun 2015 | - | $23.73 M(+61.2%) |
| Mar 2015 | - | $14.72 M(+13.0%) |
| Dec 2014 | $13.02 M(+36.5%) | $13.02 M(+12.2%) |
| Sep 2014 | - | $11.61 M(+22.1%) |
| Jun 2014 | - | $9.50 M(+35.9%) |
| Mar 2014 | - | $6.99 M(-26.7%) |
| Dec 2013 | $9.54 M(+139.9%) | $9.54 M(+28.3%) |
| Sep 2013 | - | $7.44 M(+87.1%) |
| Dec 2012 | $3.98 M(+167.6%) | $3.98 M |
| Dec 2011 | $1.49 M | - |
FAQ
- What is Ultragenyx Pharmaceutical annual total liabilities?
- What is the all time high annual total liabilities for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical annual total liabilities year-on-year change?
- What is Ultragenyx Pharmaceutical quarterly total liabilities?
- What is the all time high quarterly total liabilities for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical quarterly total liabilities year-on-year change?
What is Ultragenyx Pharmaceutical annual total liabilities?
The current annual total liabilities of RARE is $1.24 B
What is the all time high annual total liabilities for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high annual total liabilities is $1.24 B
What is Ultragenyx Pharmaceutical annual total liabilities year-on-year change?
Over the past year, RARE annual total liabilities has changed by +$25.56 M (+2.10%)
What is Ultragenyx Pharmaceutical quarterly total liabilities?
The current quarterly total liabilities of RARE is $1.24 B
What is the all time high quarterly total liabilities for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high quarterly total liabilities is $1.24 B
What is Ultragenyx Pharmaceutical quarterly total liabilities year-on-year change?
Over the past year, RARE quarterly total liabilities has changed by +$25.56 M (+2.10%)